BioMedPartners

TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

Idiag AG is a Swiss company that specializes in designing, manufacturing, and marketing healthcare equipment aimed at enhancing health and performance. Among its notable products are SpinalMouse, a tool for assessing back conditions; STMedical, a respiratory therapy device; SpiroTiger, which focuses on respiratory training; and Biacorpus RX 4000, used for bio-electrical impedance analysis to evaluate body composition. The company also offers weight management solutions like Fitmate and various spinal analysis and therapy products, including ValedoShape and ValedoMotion. Idiag serves a diverse clientele, including doctors, physiotherapists, athletes, clinics, and health centers, distributing its products through dealers in Switzerland, Germany, and internationally. Established in 1993 and headquartered in Fehraltorf, Switzerland, Idiag aims to bridge research, development, and market readiness for innovative medical technologies, providing a platform for universities and innovation centers to bring their concepts to market.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.